[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![WallStSai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::90807052.png) S A I ™️ [@WallStSai](/creator/twitter/WallStSai) on x 7087 followers
Created: 2025-07-09 10:43:02 UTC

Recent acquisitions of $BPMC ($9.5B) $VRNA ($10B) are clearly pointing $MDGL Madrigal could easily be the next M&A target for $XBI big pharma now as they rush to replace LOE’s and bigger revenue holes. Madrigal may attract $12.5-$15 billion ( fully diluted shares ) in buyout premium according to current stock valuations 

Similar to Verona $VRNA, it’s a single product company and obtained FDA approval for ‘Rezdiffra’ in 2024. Company is currently working on MASH F4C trials. With EMA decision in August,  $MDGL Madrigal is expected to make $1-$1.2 billion net sales in 2026 

$XBI $BMY $PFE $GILD #MASH @mroliverbarnes


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942897275585401283/c:line.svg)

**Related Topics**
[acquisition](/topic/acquisition)
[stocks](/topic/stocks)
[$xbi](/topic/$xbi)
[$10b](/topic/$10b)
[$vrna](/topic/$vrna)
[$95b](/topic/$95b)
[$bpmc](/topic/$bpmc)
[$mdgl](/topic/$mdgl)

[Post Link](https://x.com/WallStSai/status/1942897275585401283)